The sample in our study after quality control:
179 glioma cases from TCGA.
(92 were released after Aug. 2009)
1306 from Illumina controls (iControls)

The sample in AGS study after quality control:
692 high-grade glioma cases
--602 from AGS
--70 glioma cases from TCGA
3,992 controls
--602 controls from AGS
--3390 from Illumina controls (iControls)

excluding SNPs with Minor Allele Frequency < 5%
excluding SNPs with P<10^-6 for Hardy-Weinberg equilibrium in either AGS controls or iControls
excluding >5% missing genotyping data in any of the four subject groups, AGS cases or controls, iControls or TCGA cases

489,781 SNPs left from 550K SNPs in our TCGA study

excluding SNPs with Minor Allele Frequency < 5%
excluding SNPs with P value< 10^-5 for Hardy-Weinberg equilibrium in either AGS controls or iControls
excluding >5% missing genotyping data in any of the four subject groups, AGS cases or controls, iControls or TCGA cases

275,895 SNPs left from 300k SNPs in AGS study